Xlife Sciences AG Transfers 12 Project Companies to Grupo Landsteiner

Xlife Sciences AG has announced a strategic exit of 12 biotech, medtech, and digital health projects to Grupo Landsteiner for USD 450 million in shares. This move aims to develop a scalable transcontinental life sciences platform. The transaction involves an asset purchase, allowing Xlife Sciences to continue its innovative pursuits while collaborating long-term with Grupo Landsteiner. Together, they plan to enhance innovation and global market reach.

The newly formed entity will pursue a NASDAQ listing in 2026. Grupo Landsteiner gains exclusive access to 40 universities and various industry stakeholders, strengthening oncology capabilities in Mexico. Significant infrastructure investments are expected to improve cancer care locally and globally. This partnership combines Swiss innovation with Latin American manufacturing, aiming for a vertically integrated company poised for sustainable growth.